Free Trial
OTCMKTS:BIXT

Bioxytran (BIXT) Stock Price, News & Analysis

Bioxytran logo
$0.15 0.00 (-1.73%)
As of 05/30/2025 03:57 PM Eastern

About Bioxytran Stock (OTCMKTS:BIXT)

Key Stats

Today's Range
$0.15
$0.16
50-Day Range
$0.10
$0.18
52-Week Range
$0.06
$0.23
Volume
59,038 shs
Average Volume
240,562 shs
Market Capitalization
$14.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was founded in 2008 and is headquartered in Needham, Massachusetts.

Receive BIXT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bioxytran and its competitors with MarketBeat's FREE daily newsletter.

BIXT Stock News Headlines

Big Oil’s big pivot
The Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle of the Utah's Black Desert. Why? Not for oil discovery. Or uranium or solar. Instead, what’s happening beneath this patch of sand is the discovery of a new kind of energy. Google, Buffett, and a even tech billionaires like Gates, Bezos, and Zuckerberg are grabbing a stake.
See More Headlines

BIXT Stock Analysis - Frequently Asked Questions

Bioxytran's stock was trading at $0.0899 at the beginning of the year. Since then, BIXT stock has increased by 64.0% and is now trading at $0.1474.
View the best growth stocks for 2025 here
.

Bioxytran, Inc. (OTCMKTS:BIXT) released its earnings results on Thursday, May, 15th. The company reported ($0.02) earnings per share (EPS) for the quarter.

Shares of BIXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bioxytran investors own include AMC Entertainment (AMC), Armata Pharmaceuticals (ARMP), bluebird bio (BLUE), Esports Entertainment Group (GMBL), Genius Group (GNS), Novavax (NVAX) and Karora Resources Inc. (RNX.TO) (RNX).

Company Calendar

Last Earnings
5/15/2025
Today
6/01/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:BIXT
Fax
N/A
Employees
2
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$4.47 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
($0.02) per share
Price / Book
-7.37

Miscellaneous

Free Float
26,440,000
Market Cap
$14.77 million
Optionable
Not Optionable
Beta
1.82
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (OTCMKTS:BIXT) was last updated on 6/1/2025 by MarketBeat.com Staff
From Our Partners